Hepatology

Normal on-Treatment ALT Linked to Reduced Hepatic Events in Hepatitis B

Normal on-Treatment ALT Linked to Reduced Hepatic Events in Hepatitis B

By

Patients with chronic hepatitis B have a lower risk of hepatic events if they achieve normal on-treatment ALT in the first 12 months of NA treatment.

CDC Issues Updated Advisory Regarding Outbreaks of Hepatitis A

CDC Issues Updated Advisory Regarding Outbreaks of Hepatitis A

By

Of the 2500 cases of hepatitis A infection reported between January 2017 and April 2018, 68% were among persons who reported drug use (injection and non-injection), homelessness, or both.

DAA Therapy May Improve Select Cognitive Domains in HCV-Infected Patients

DAA Therapy May Improve Select Cognitive Domains in HCV-Infected Patients

Successful DAA therapy may lead to cognitive improvement in several domains in HCV-infected patients.

High Costs for Diagnosis, Care of Nonalcoholic Fatty Liver Disease

High Costs for Diagnosis, Care of Nonalcoholic Fatty Liver Disease

Costs were significantly higher than total annual costs per matched control with similar comorbidities.

Hepatitis C-Exposed Infants Not Adequately Screened

Hepatitis C-Exposed Infants Not Adequately Screened

Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

By

The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.

Sofosbuvir Improves Renal Safety in Patients With Chronic Hepatitis C

Sofosbuvir Improves Renal Safety in Patients With Chronic Hepatitis C

Patients with mild, moderate renal impairment showed improvement in renal biomarkers over one year

Novel Medicaid Strategy Proposed to Increase Access to HCV Treatment

Novel Medicaid Strategy Proposed to Increase Access to HCV Treatment

A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

By

A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.

More Comprehensive HDV Surveillance Needed in High-Risk Individuals

More Comprehensive HDV Surveillance Needed in High-Risk Individuals

Future studies might focus on the use of electronic medical record warning systems or other prompts to improve diagnostic test use in at-risk individuals.

Metabolic Syndrome Common With Chronic Hepatitis B Infection

Metabolic Syndrome Common With Chronic Hepatitis B Infection

Metabolic syndrome also associated with higher alanine aminotransferase levels longitudinally

Hepatitis C Screening Increasing Among Baby Boomers

Hepatitis C Screening Increasing Among Baby Boomers

Screening prevalence 11.5 to 12.8%; similar rate for cohort born from 1966 to 1985

Effectiveness of Shortened Treatment Regimen for Hepatitis C Assessed

Effectiveness of Shortened Treatment Regimen for Hepatitis C Assessed

In this large, real-world cohort of patients with chronic hepatitis C virus infection, equivalent sustained virologic response rates were found with both 8-week and 12-week treatment.

End-of-Treatment HBsAg Levels May Predict HBV Relapse in Chronic Hepatitis B

End-of-Treatment HBsAg Levels May Predict HBV Relapse in Chronic Hepatitis B

End-of-treatment HBsAg levels may be a clinically useful biomarker to predict HBV relapse in patients with chronic hepatitis B regardless of HBeAg status.

Obesity Can Negatively Affect Liver in Children As Young As 8

Obesity Can Negatively Affect Liver in Children As Young As 8

Increased adiposity in childhood may negatively impact liver function in children as young as 8 years old.

Direct-Acting Antivirals Improve Liver Transplant Survival

Direct-Acting Antivirals Improve Liver Transplant Survival

Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.

BMI associated with hepatocellular carcinoma risk for patients with chronic hepatitis B virus

BMI associated with hepatocellular carcinoma risk for patients with chronic hepatitis B virus

BMI is positively correlated with increased hepatocellular carcinoma in patients with chronic HBV, though the risk is greater in women.

HCV treatment with direct antiviral agents improves carotid atherosclerosis

HCV treatment with direct antiviral agents improves carotid atherosclerosis

By

Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.

Prophylaxis may protect kidney recipients from HCV

Prophylaxis may protect kidney recipients from HCV

Prophylaxis safely, effectively prevents HCV transmittance in noninfected patients receiving kidney transplants from HCV-positive donors.

Maternal TDF not effective in reducing hepatitis B transmission

Maternal TDF not effective in reducing hepatitis B transmission

TDF did not reduce mother-to-child HBV transmission in mothers taking hepatitis B Ig and HBV vaccine.

Drug combination effective for hepatitis C

Drug combination effective for hepatitis C

By

Elbasvir and grazoprevir, taken in combination for 12 weeks, successfully treated virologic response in patient with hepatitis C genotype 1b.

Alternatives to whole liver transplants possible for children

Alternatives to whole liver transplants possible for children

Technical variant grafts may be better than whole grafts for living donor liver transplants in children.

Hepatitis B infection prevention: ACIP updated recommendations

Hepatitis B infection prevention: ACIP updated recommendations

By

The Work Group who authored the new recommendations was made up of professionals from academic medicine, federal and state public health agencies, and medical societies.

Once daily glecaprevir-pibrentasvir treats HCV genotype 1,3

Once daily glecaprevir-pibrentasvir treats HCV genotype 1,3

Once daily glecaprevir-pibrentasvir for 8 or 12 weeks successfully treated HCV genotype 1 and 3.

Primary gastrinomas of the hepatobiliary tract may occur in patients with Zollinger-Ellison syndrome

Primary gastrinomas of the hepatobiliary tract may occur in patients with Zollinger-Ellison syndrome

By

Lymph nodes proximal to hepatic or biliary gastrinomas will likely require extraction as many in the surround region will have metastasized.

HCV treatment hinders liver fibrosis progression

HCV treatment hinders liver fibrosis progression

By

Patients with chronic HCV with a sustained virologic response were more likely to have a reduced progression of liver fibrosis.

FDA approves Heplisav-B vaccine for hepatitis B treatment

FDA approves Heplisav-B vaccine for hepatitis B treatment

By

The Food and Drug Administration (FDA) has approved Heplisav-B for the prevention of infection caused by all known subtypes of hepatitis B virus.

Hepatitis increases mortality rates in HIV patients

Hepatitis increases mortality rates in HIV patients

By

Hepatitis B and hepatitis C may increase mortality risks in HIV patients.

Nurse practitioner treatment of hepatitis C in primary care

Nurse practitioner treatment of hepatitis C in primary care

By

Hepatitis C treatment improves outcomes and experiences for patient and provider.

Epsom salt may cause liver injury in predisposed patients

Epsom salt may cause liver injury in predisposed patients

A 38-year old nonalcoholic patient consumed Epsom salt in large quantities for a short period of time and developed jaundice and steatohepatitis.

Sign Up for Free e-newsletters